Leveling Up Primary Biliary Cholangitis Management:
Optimizing Biomarker Surveillance, Addressing PBC-related Pruritus and Application of Real-World Evidence

Faculty

Hanna Blaney, MD, MPH

Transplant Hepatology Fellow,
MedStar Health
Georgetown University
Kensington, MD
Anahita Rabiee, MD, MHS

Transplant Hepatologist,
Instructor, Digestive Diseases Section
Yale School of Medicine
Fairfield, CT
Atoosa Rabiee, MD

Washington DC VA Medical Center
Bethesda, MD

Program Overview

The need for improved understanding and application of advancements in the management of primary biliary cholangitis (PBC) poses a significant challenge for healthcare professionals. Gaps exist in recognizing the consequences of delayed initiation of both first- and second-line treatments, comprehending the importance of extensive biomarker analysis beyond ALP, and managing PBC-associated pruritus effectively. Additionally, there is a demonstrated necessity for integrating real-world evidence into clinical practice to gain a comprehensive understanding of PBC-related factors. Continuous education for healthcare professionals is essential to enhance their grasp of current and emerging PBC developments. Closing these knowledge gaps will accelerate the adoption of effective management strategies, ultimately leading to optimal patient care outcomes. 

Target Audience

This educational initiative is designed for specialty clinicians (gastroenterologists hepatologists and immunologists), including advanced practice clinicians and nurses.  

Learning Objectives

Upon completion of this activity, the participant should be able to:

  • IDENTIFY the need for comprehensive understanding of the effect and impact of PBC therapy on clinical outcomes.
  • DESCRIBE factors contributing to low initiation rates of PBC therapy and strategies to address barriers to specialty PBC care.
  • ASSESS the role of biomarker analysis in informing the timely initiation of second-line treatment to reduce the likelihood of disease progression.
  • RECOGNIZE effects of PBC-related pruritus on quality of life and the role of pharmacologic and nonpharmacologic pruritus management strategies.
  • REVIEW real-world evidence to enhance decision-making in clinical practice.

Educational Activities

Social Media Broadcasts
Podcasts
Threads
Clinical Support Tools

Clinical Resource Center

Credit Amount: N/A
Credit Type: Non-Certified

SOCIAL MEDIA BROADCAST ONE

Credit Amount: 0.25
Credit Type: ACCME, ANCC
Release: September 24, 2024
Expiration: September 24, 2025

SOCIAL MEDIA BROADCAST TWO

Credit Amount: 0.25
Credit Type: ACCME, ANCC
Release: September 26, 2024
Expiration: September 26, 2025

PODCAST ONE

Credit Amount: 0.25
Credit Type: ACCME, ANCC
Release: September 25, 2024
Expiration: September 25, 2025

PODCAST TWO

Credit Amount: 0.25
Credit Type: ACCME, ANCC
Release: September 27, 2024
Expiration: September 27, 2025

THREAD ONE

Credit Amount: N/A
Credit Type: Non-Certified

THREAD TWO

Credit Amount: N/A
Credit Type: Non-Certified

This activity is jointly provided by Global Education Group and Iridium Continuing Education.

SUPPORTER ACKNOWLEDGEMENT
This educational activity is supported by an independent educational grant from Intercept Pharmaceuticals, Inc.

Maximum Credit Amount: 1.00
Credit Type: ACCME, ANCC
Release: September 9, 2024
Expiration: September 12, 2025

info@iridiumce.com